NO323646B1 - Nukleinsyremolekyl, nukleinsyreprobe, polypeptid, antistoff, hybridom, kit, anvendelse samt fremgangsmate. - Google Patents

Nukleinsyremolekyl, nukleinsyreprobe, polypeptid, antistoff, hybridom, kit, anvendelse samt fremgangsmate. Download PDF

Info

Publication number
NO323646B1
NO323646B1 NO19982794A NO982794A NO323646B1 NO 323646 B1 NO323646 B1 NO 323646B1 NO 19982794 A NO19982794 A NO 19982794A NO 982794 A NO982794 A NO 982794A NO 323646 B1 NO323646 B1 NO 323646B1
Authority
NO
Norway
Prior art keywords
aur
polypeptide
seq
acid sequence
amino acids
Prior art date
Application number
NO19982794A
Other languages
English (en)
Norwegian (no)
Other versions
NO982794L (no
NO982794D0 (no
Inventor
Gregory D Plowman
Kevin G Moissie
Original Assignee
Sugen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26678652&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO323646(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sugen Inc filed Critical Sugen Inc
Publication of NO982794D0 publication Critical patent/NO982794D0/no
Publication of NO982794L publication Critical patent/NO982794L/no
Publication of NO323646B1 publication Critical patent/NO323646B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
NO19982794A 1995-12-18 1998-06-17 Nukleinsyremolekyl, nukleinsyreprobe, polypeptid, antistoff, hybridom, kit, anvendelse samt fremgangsmate. NO323646B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US880995P 1995-12-18 1995-12-18
US2394396P 1996-08-14 1996-08-14
PCT/US1996/018859 WO1997022702A1 (en) 1995-12-18 1996-11-25 Diagnosis and treatment of aur-1 and/or aur-2 related disorders

Publications (3)

Publication Number Publication Date
NO982794D0 NO982794D0 (no) 1998-06-17
NO982794L NO982794L (no) 1998-08-18
NO323646B1 true NO323646B1 (no) 2007-06-18

Family

ID=26678652

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19982794A NO323646B1 (no) 1995-12-18 1998-06-17 Nukleinsyremolekyl, nukleinsyreprobe, polypeptid, antistoff, hybridom, kit, anvendelse samt fremgangsmate.

Country Status (15)

Country Link
US (2) US5962312A (de)
EP (2) EP1655369A1 (de)
JP (1) JP3944241B2 (de)
KR (1) KR100459052B1 (de)
AT (1) ATE315654T1 (de)
AU (1) AU716330B2 (de)
CA (1) CA2239692C (de)
DE (1) DE69635740T2 (de)
DK (1) DK0868519T3 (de)
ES (1) ES2255715T3 (de)
IL (1) IL124728A (de)
NO (1) NO323646B1 (de)
NZ (1) NZ323795A (de)
PT (1) PT868519E (de)
WO (1) WO1997022702A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716575B2 (en) 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
US6759212B1 (en) * 1997-08-15 2004-07-06 Chugai Seiyaku Kabushiki Kaisha Cell cycle-regulating proteins
US5962232A (en) * 1998-01-30 1999-10-05 Incyte Pharmaceuticals, Inc. Protein kinase molecules
SK3822002A3 (en) 1999-09-21 2002-10-08 Astrazeneca Ab Quinazoline derivatives, process for the preparation thereof and their use
US6352858B1 (en) 2000-09-11 2002-03-05 Isis Pharmaceuticals, Inc. Antisense modulation of BTAK expression
JP2002236125A (ja) * 2001-02-06 2002-08-23 Igaku Seibutsugaku Kenkyusho:Kk タンパク質リン酸化酵素活性の測定方法、測定用キット及び測定に用いる抗体
AU2002322775A1 (en) * 2001-07-27 2003-02-17 The Regents Of The University Of California Stk15 (stk6) gene polymorphism and methods of determining cancer risk
US20050216961A1 (en) * 2002-03-28 2005-09-29 Delaney Allen D Cancer associated protein kinases and their uses
FR2840905B1 (fr) * 2002-06-12 2006-07-07 Centre Nat Rech Scient Anticorps monoclonal anti-aurora-a, son procede d'obtention, et ses utilisations dans le diagnostic et le traitement des cancers
US7444273B1 (en) * 2002-06-21 2008-10-28 Takeda San Diego, Inc. Crystallization of aurora/LPL1P-related kinase
US20120045390A1 (en) * 2002-09-11 2012-02-23 Genentech, Inc. Composition and Methods for the Diagnosis and Treatment of Tumor
WO2004046386A1 (en) * 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
RU2350611C1 (ru) 2002-12-24 2009-03-27 Астразенека Аб Производные фосфонооксихиназолина и их фармацевтическое применение
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
WO2004071572A2 (en) * 2003-02-06 2004-08-26 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
CA2516553C (en) * 2003-02-20 2013-04-16 Genomic Health, Inc. Use of intronic rna to measure gene expression
CA2527321A1 (en) * 2003-05-30 2004-12-23 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
EP3170906B1 (de) 2003-06-24 2018-08-22 Genomic Health, Inc. Vorhersage der wahrscheinlichkeit eines wiederauftretens von krebs
EP3330875B1 (de) * 2003-07-10 2021-12-01 Genomic Health, Inc. Expressionsprofilalgorithmus und -test zur prognose des wiederauftretens von brustkrebs
CA2542656A1 (en) * 2003-10-16 2005-05-06 Genomic Health, Inc. Qrt-pcr assay system for gene expression profiling
WO2005061519A1 (en) 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
CA2551267C (en) * 2003-12-23 2012-05-01 Genomic Health, Inc. Universal amplification of fragmented rna
US7871769B2 (en) * 2004-04-09 2011-01-18 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
US7754714B2 (en) * 2004-05-18 2010-07-13 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
WO2006031273A2 (en) * 2004-06-18 2006-03-23 Cytokinetics, Inc. Cellular phenotype
US7550598B2 (en) 2004-08-18 2009-06-23 Takeda Pharmaceutical Company Limited Kinase inhibitors
AR050948A1 (es) 2004-09-24 2006-12-06 Hoffmann La Roche Derivados de ftalazinona; su obtencion y su utilizacion en la fabricacion de medicamentos para el tratamiento del cancer.
US7285569B2 (en) 2004-09-24 2007-10-23 Hoff Hoffmann-La Roche Inc. Tricycles, their manufacture and use as pharmaceutical agents
DE602005023333D1 (de) 2004-10-15 2010-10-14 Takeda Pharmaceutical Kinaseinhibitoren
CA2585571C (en) * 2004-11-05 2020-01-21 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
CA2585561C (en) * 2004-11-05 2018-07-17 Genomic Health, Inc. Esr1, pgr, bcl2 and scube2 group score as indicators of breast cancer prognosis and prediction of treatment response
GB2420559B (en) * 2004-11-15 2008-08-06 Rigel Pharmaceuticals Inc Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
KR20070113286A (ko) 2005-04-14 2007-11-28 에프. 호프만-라 로슈 아게 아미노피라졸 유도체, 이의 제조 및 약학 제제로서의 용도
US20070082327A1 (en) * 2005-09-09 2007-04-12 Cytokinetics, Inc. A Delaware Corporation Cellular phenotype
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US20080020412A1 (en) * 2006-01-03 2008-01-24 Romanowski Michael J Aurora expression constructs
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors
JP5279063B2 (ja) * 2007-05-25 2013-09-04 国立大学法人愛媛大学 Ｈｌａ−ａ２拘束性抗原ペプチドおよびその用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5283173A (en) * 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
WO1992014748A1 (en) * 1991-02-22 1992-09-03 American Cyanamid Company Identification of a novel human receptor tyrosine kinase gene
AU677834B2 (en) * 1993-04-07 1997-05-08 Cancer Research Ventures Limited Methods for screening of substances for therapeutic activityand yeast for use therein
US5830648A (en) * 1995-05-05 1998-11-03 Sugen, Inc. Assay and method for transcript imaging

Also Published As

Publication number Publication date
NZ323795A (en) 2000-01-28
EP1655369A1 (de) 2006-05-10
EP0868519B1 (de) 2006-01-11
WO1997022702A1 (en) 1997-06-26
NO982794L (no) 1998-08-18
PT868519E (pt) 2006-05-31
CA2239692C (en) 2008-12-16
KR20000064437A (ko) 2000-11-06
DE69635740T2 (de) 2006-09-14
IL124728A (en) 2007-06-03
US5972676A (en) 1999-10-26
AU1082697A (en) 1997-07-14
JP3944241B2 (ja) 2007-07-11
US5962312A (en) 1999-10-05
NO982794D0 (no) 1998-06-17
DE69635740D1 (de) 2006-04-06
ES2255715T3 (es) 2006-07-01
CA2239692A1 (en) 1997-06-26
ATE315654T1 (de) 2006-02-15
DK0868519T3 (da) 2006-05-08
KR100459052B1 (ko) 2005-01-15
JP2000502895A (ja) 2000-03-14
IL124728A0 (en) 1999-01-26
AU716330B2 (en) 2000-02-24
EP0868519A1 (de) 1998-10-07

Similar Documents

Publication Publication Date Title
CA2239692C (en) Diagnosis and treatment of aur-1 and/or aur-2 related disorders
EP1051500B1 (de) Diagnose und behandlung von aur1 und/oder aur2 verwandten erkrankungen
US7119174B2 (en) Diagnosis and treatment of AUR1 and/or AUR2 related disorders
US6495353B1 (en) Human orthologues of wart
US20080009610A1 (en) Diagnosis and treatment of PTP related disorders
CA2288221A1 (en) Diagnosis and treatment of phosphatase 0r kinase-related disorders
US6136581A (en) Kinase genes and uses
US6844177B2 (en) Diagnosis and treatment of PTP04 related disorders
WO1996037610A2 (en) Cck-4, a receptor tyrosine kinase, and methods for diagnosis and treatment of cck-4 signal transduction disorders
US5895813A (en) Diagnosis and treatment of TKA-1 related disorders
US6342593B1 (en) Diagnosis and treatment of ALP related disorders
US5922842A (en) Tyrosine kinase associated polypeptides
MXPA98004934A (en) Diagnosis and treatment of alterations related to aur-1 and / or au
WO1999027099A1 (en) Orf, a substrate for extracellular signal-regulated kinase, erk-6, and related methods
WO2001092491A2 (en) Mammalian protein phosphatases identified by in-silico analysis

Legal Events

Date Code Title Description
MK1K Patent expired